These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 31758597

  • 1. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S.
    Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL.
    Int J Hematol; 2021 Jan; 113(1):92-99. PubMed ID: 32951163
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Kobayashi Y, Yamauchi T, Kiyoi H, Sakura T, Hata T, Ando K, Watabe A, Harada A, Taube T, Miyazaki Y, Naoe T.
    Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, Tontsch-Grunt U, Wernitznig A, Savarese F, Hofmann MH, Albrecht C, Geiselmann L, Reschke M, Garin-Chesa P, Zuber J, Moll J, Adolf GR, Kraut N.
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C, Dragoi D, Frey AV, Thurig K, Lübbert M, Wäsch R, Bogatyreva L, Hauschke D, Lassmann S, Werner M, May AM.
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL, Chen JP, Huang YS, Tsai YC, Tsai MH, Jaw FS, Cheng JC, Kuo SH, Shieh MJ.
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [Abstract] [Full Text] [Related]

  • 7. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q.
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [Abstract] [Full Text] [Related]

  • 8. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J, Lardon F, Deschoolmeester V, De Pauw I, Vermorken JB, Specenier P, Pauwels P, Peeters M, Wouters A.
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC.
    Br J Cancer; 2014 May 13; 110(10):2434-40. PubMed ID: 24755882
    [Abstract] [Full Text] [Related]

  • 10. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A.
    Mol Oncol; 2019 May 13; 13(5):1196-1213. PubMed ID: 30859681
    [Abstract] [Full Text] [Related]

  • 11. Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
    Goroshchuk O, Kolosenko I, Kunold E, Vidarsdottir L, Pirmoradian M, Azimi A, Jafari R, Palm-Apergi C.
    FASEB J; 2021 Jul 13; 35(7):e21741. PubMed ID: 34143546
    [Abstract] [Full Text] [Related]

  • 12. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B, within the ITCC Biology and Preclinical Evaluation Committee.
    Anticancer Res; 2016 Feb 13; 36(2):599-609. PubMed ID: 26851014
    [Abstract] [Full Text] [Related]

  • 13. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.
    Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau G.
    Blood Adv; 2019 Feb 26; 3(4):552-563. PubMed ID: 30782614
    [Abstract] [Full Text] [Related]

  • 14. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
    Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.
    Leukemia; 2016 Jan 26; 30(1):112-23. PubMed ID: 26153654
    [Abstract] [Full Text] [Related]

  • 15. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
    Czibere A, Prall WC, Zerbini LF, Grall F, Craigie EC, Ulrich SD, Giagounidis AA, Haas R, Libermann TA, Aivado M.
    Cell Cycle; 2005 Jun 26; 4(6):812-7. PubMed ID: 15970671
    [Abstract] [Full Text] [Related]

  • 16. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F.
    Hematol Oncol; 2015 Jun 26; 33(2):57-66. PubMed ID: 24777753
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S.
    Oncotarget; 2017 May 09; 8(19):31478-31493. PubMed ID: 28416758
    [Abstract] [Full Text] [Related]

  • 20. Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
    Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U.
    BMC Cancer; 2022 May 21; 22(1):569. PubMed ID: 35597904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.